位置：成果数据库 > 期刊 > 期刊详情页
Yhhu3813 is a novel selective inhibitor of c - Met Kinase that inhibits c - Met - dependent neoplast
  • 期刊名称：Acta Pharmacologica Sinica
  • 时间：0
  • 页码：-
  • 相关项目：靶向c-Met抑制剂药效监控标志物的发现研究
作者： C He|J Ai|W Xing|Y Chen|H Zhang...|
同期刊论文项目
靶向c-Met抑制剂药效监控标志物的发现研究
期刊论文 19
同项目期刊论文
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplasti
Design and synthesis of 3,3'-biscoumarin-based c-Met inhibitors.
Discovery of Anilinopyrimidines as Dual Inhibitors of c-Met and VEGFR-2: Synthesis, SAR, and Ce
O-Linked Triazolotriazines: Potent and Selective c-Met Inhibitors.
Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory
SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits
Synthesis and biological evaluation of 2 - amino - 5 - aryl - 3 - benzylthiopyridine scaffold based
Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]napht
SOMG-833, a novel selective c-MET inhibitor, blocks c-MET-dependent neoplastic effects and exer
Discovery of novel type II c-Met inhibitors based on BMS-777607.
Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase I
Yhhu3813 is a novel selective inhibitor of c-Met kinase that inhibits c-Met-dependent neoplastic phenotypes of human cancer cells